Life Scientist > Health & Medical

AustCancer miffed by market reaction

25 November, 2002 by Pete Young

Cancer vaccine developer Australian Cancer Technology is mystified and disappointed by negative share market reaction to positive news from human trials of its cancer vaccine, Pentrix.


CSL celebrates cervical cancer vaccine success

21 November, 2002 by Graeme O'Neill

Cancer research is all hard slog, a long journey of many small steps, punctuated all too rarely by a genuine leap forward -- like the one announced today by CSL and its partner, pharma giant Merck and Co.


Sirtex moves toward US target

21 November, 2002 by Melissa Trudinger

Sirtex Medical is on track to achieve its goal of rolling out its SIR-Spheres cancer treatment in ten US hospitals by the end of the year, according to CEO Colin Sutton, with the ninth centre at Emory University Hospital treating its first two patients last week.


UTS brings in American to head infectious disease institute

19 November, 2002 by Graeme O'Neill

The University of Technology, Sydney (UTS) has appointed eminent American parasitologist Prof Michael Wallach as director of its new Institute for the Biotechnology of Infectious Diseases.


Research grant to help crystallise malaria mystery

18 November, 2002 by Pete Young

Encouraging results are flowing for Australian researchers using computer graphics to find inhibitors of a protein that plays a pivotal role in the life cycle of the parasite that causes malaria.


Cancer treatment targeted by new QIMR agreement

13 November, 2002 by Pete Young

Gene discovery and drug development company diaDexus has signed a deal with the Queensland Institute for Medical Research (QIMR) concerning a novel molecule with potential for treating cancers in both males and females.


Monash pain research nets UK licensing deal

08 November, 2002 by Melissa Trudinger

A new approach to treating pain has been licensed to British company RiboTargets by Monash University in a deal brokered by Victorian technology commercialisation company Biocomm.


Panbio moves into DNA diagnostics

05 November, 2002 by Pete Young

Medical diagnostics company Panbio Ltd, which has built its business around traditional microbiology kits, is moving into the fast-growing field of DNA probe-based diagnostics.


Gradipore says at AGM it will change

01 November, 2002 by David Binning

Having been promised the world, impatient shareholders of Sydney-based separations company Gradipore were demanding answers at Thursday's company AGM at the Australian Stock Exchange.


Medica achieves funding target in placement

30 October, 2002 by Melissa Trudinger

Medica Holdings has raised $3.25 million in a private placement to leading Australian institutional investors.


Metabolic teams with BresaGen to produce anti-obesity compound

30 October, 2002 by Graeme O'Neill

Melbourne biotechnology company Metabolic Pharmaceuticals has engaged Adelaide biotech BresaGen to develop a scaleable production system for its promising anti-obesity compound AOD9604.


Sirtex gains European approval

23 October, 2002 by Pete Young

Anti-cancer company Sirtex Medical has been given the green light to begin marketing and sales of its lead product SIR-Spheres in the European Community.


Interview: Brain research resonates for BRI scientist

23 October, 2002 by Melissa Trudinger

Tucked away in the corner of the Austin and Repatriation Medical Centre campus in Melbourne suburb of Heidelberg is the Brain Research Institute (BRI), devoted to research into epilepsy and other neural disorders, as well as the function of the healthy brain.


Nobel Laureates to speak at cancer conference

18 October, 2002 by Graeme O'Neill

The 2003 Lorne Protein and Cancer Conferences have snared two of the biggest names in medical research as guest speakers next February: 2002 Nobel Laureates Prof Sir Sidney Brenner and Prof Robert Horovitz.


Children's cancer targeted by ARC grant

18 October, 2002 by Graeme O'Neill

The survival rate of children with childhood cancers has increased spectacularly since the early 1960s, from a bleak 10 per cent to around 75 per cent today. One notable exception to the trend is neuroblastoma, with a survival rate below 50 per cent.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd